OMEROS CORP Proceeds from Sale of Available-for-sale Securities
OMEROS CORP (OMER) reported Proceeds from Sale of Available-for-sale Securities of $11.75 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2019-05-09
- OMEROS CORP proceeds from sale of available-for-sale securities for the quarter ending 2019-03-31 was $11.75M, a 30.56% increase year-over-year.
- OMEROS CORP proceeds from sale of available-for-sale securities for the quarter ending 2018-12-31 was $21.00M, a 271.75% increase year-over-year.
- OMEROS CORP proceeds from sale of available-for-sale securities for the quarter ending 2018-09-30 was $33.50M, a 644.28% increase year-over-year.
- OMEROS CORP proceeds from sale of available-for-sale securities for the quarter ending 2018-06-30 was $31.00M, a 404.07% increase year-over-year.
- OMEROS CORP proceeds from sale of available-for-sale securities for fiscal 2018 was $94.50M, a 236.56% increase from fiscal 2017.
- OMEROS CORP proceeds from sale of available-for-sale securities for fiscal 2017 was $28.08M, a 51.39% decline from fiscal 2016.
- OMEROS CORP proceeds from sale of available-for-sale securities for fiscal 2016 was $57.76M, a 19.11% decline from fiscal 2015.
- OMEROS CORP proceeds from sale of available-for-sale securities for fiscal 2015 was $71.40M, a 9.79% increase from fiscal 2014.
| Period end | Proceeds from Sale of Available-for-sale Securities 3 month | Proceeds from Sale of Available-for-sale Securities 6 month | Proceeds from Sale of Available-for-sale Securities 9 month | Proceeds from Sale of Available-for-sale Securities 12 month | Proceeds from Sale of Available-for-sale Securities 204 month | Proceeds from Sale of Available-for-sale Securities 207 month |
|---|---|---|---|---|---|---|
| 2019-03-31 | $11.75M 10-Q · filed 2019-05-09 | $32.75M derived: sum of 2 quarters · filed 2019-05-09 | $66.25M derived: sum of 3 quarters · filed 2019-05-09 | $97.25M derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2018-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $54.50M derived: sum of 2 quarters · filed 2019-03-01 | $85.50M derived: sum of 3 quarters · filed 2019-03-01 | $94.50M 10-K · filed 2019-03-01 | ||
| 2018-09-30 | $33.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $64.50M derived: sum of 2 quarters · filed 2018-11-08 | $73.50M 10-Q · filed 2018-11-08 | $79.15M derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2018-06-30 | $31.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $40.00M 10-Q · filed 2018-08-09 | $45.65M derived: sum of 3 quarters · filed 2019-05-09 | $50.15M derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2018-03-31 | $9.00M 10-Q · filed 2019-05-09 | $14.65M derived: sum of 2 quarters · filed 2019-05-09 | $19.15M derived: sum of 3 quarters · filed 2019-05-09 | $25.30M derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $10.15M derived: sum of 2 quarters · filed 2019-03-01 | $16.30M derived: sum of 3 quarters · filed 2019-03-01 | $28.08M 10-K · filed 2019-03-01 | ||
| 2017-09-30 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $10.65M derived: sum of 2 quarters · filed 2018-11-08 | $22.43M 10-Q · filed 2018-11-08 | $32.31M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-06-30 | $6.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $17.93M 10-Q · filed 2018-08-09 | $27.81M derived: sum of 3 quarters · filed 2019-03-01 | $44.81M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-03-31 | $11.78M 10-Q · filed 2018-05-10 | $21.66M derived: sum of 2 quarters · filed 2019-03-01 | $38.66M derived: sum of 3 quarters · filed 2019-03-01 | $54.88M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2016-12-31 | $9.88M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $26.88M derived: sum of 2 quarters · filed 2019-03-01 | $43.11M derived: sum of 3 quarters · filed 2019-03-01 | $57.76M 10-K · filed 2019-03-01 | ||
| 2016-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $33.23M derived: sum of 2 quarters · filed 2017-11-09 | $47.88M 10-Q · filed 2017-11-09 | $67.72M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-06-30 | $16.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $30.88M 10-Q · filed 2017-08-08 | $50.73M derived: sum of 3 quarters · filed 2018-03-01 | $65.22M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-03-31 | $14.65M 10-Q · filed 2017-05-10 | $34.50M derived: sum of 2 quarters · filed 2018-03-01 | $49.00M derived: sum of 3 quarters · filed 2018-03-01 | $68.75M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2015-12-31 | $19.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $34.35M derived: sum of 2 quarters · filed 2018-03-01 | $54.10M derived: sum of 3 quarters · filed 2018-03-01 | $71.40M 10-K · filed 2018-03-01 | ||
| 2015-09-30 | $14.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $34.25M derived: sum of 2 quarters · filed 2016-11-09 | $51.55M 10-Q · filed 2016-11-09 | $66.05M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-06-30 | $19.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $37.05M 10-Q · filed 2016-08-09 | $51.55M derived: sum of 3 quarters · filed 2017-03-16 | $66.45M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-03-31 | $17.30M 10-Q · filed 2016-05-10 | $31.80M derived: sum of 2 quarters · filed 2017-03-16 | $46.70M derived: sum of 3 quarters · filed 2017-03-16 | $62.40M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2014-12-31 | $14.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $29.40M derived: sum of 2 quarters · filed 2017-03-16 | $45.10M derived: sum of 3 quarters · filed 2017-03-16 | $65.03M 10-K · filed 2017-03-16 | ||
| 2014-09-30 | $14.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $30.60M derived: sum of 2 quarters · filed 2015-11-09 | $50.53M 10-Q · filed 2015-11-09 | $69.88M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-06-30 | $15.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $35.63M 10-Q · filed 2015-08-10 | $54.98M derived: sum of 3 quarters · filed 2016-03-15 | $68.83M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-03-31 | $19.93M 10-Q · filed 2015-05-11 | $39.28M derived: sum of 2 quarters · filed 2016-03-15 | $53.13M derived: sum of 3 quarters · filed 2016-03-15 | $62.98M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2013-12-31 | $19.35M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $33.19M derived: sum of 2 quarters · filed 2016-03-15 | $43.05M derived: sum of 3 quarters · filed 2016-03-15 | $55.30M 10-K · filed 2016-03-15 | ||
| 2013-09-30 | $13.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $23.70M derived: sum of 2 quarters · filed 2014-11-10 | $35.95M 10-Q · filed 2014-11-10 | $55.41M derived: sum of 4 quarters · filed 2015-03-16 | ||
| 2013-06-30 | $9.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $22.10M 10-Q · filed 2014-08-11 | $41.57M derived: sum of 3 quarters · filed 2015-03-16 | $50.82M derived: sum of 4 quarters · filed 2015-03-16 | ||
| 2013-03-31 | $12.25M 10-Q · filed 2014-05-12 | $31.72M derived: sum of 2 quarters · filed 2015-03-16 | $40.97M derived: sum of 3 quarters · filed 2015-03-16 | $41.78M derived: sum of 4 quarters · filed 2015-03-16 | ||
| 2012-12-31 | $19.47M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $28.72M derived: sum of 2 quarters · filed 2015-03-16 | $29.53M derived: sum of 3 quarters · filed 2015-03-16 | $49.28M 10-K · filed 2015-03-16 | ||
| 2012-09-30 | $9.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $10.06M derived: sum of 2 quarters · filed 2013-11-07 | $29.82M 10-Q · filed 2013-11-07 | $37.22M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2012-06-30 | $815.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $20.57M 10-Q · filed 2013-08-09 | $27.96M derived: sum of 3 quarters · filed 2014-03-13 | $32.72M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2012-03-31 | $19.75M 10-Q · filed 2013-05-09 | $27.15M derived: sum of 2 quarters · filed 2014-03-13 | $31.90M derived: sum of 3 quarters · filed 2014-03-13 | $38.90M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2011-12-31 | $7.40M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | $12.15M derived: sum of 2 quarters · filed 2014-03-13 | $19.15M derived: sum of 3 quarters · filed 2014-03-13 | $27.15M 10-K · filed 2014-03-13 | ||
| 2011-09-30 | $4.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $11.75M derived: sum of 2 quarters · filed 2012-11-09 | $19.75M 10-Q · filed 2012-11-09 | $31.75M derived: sum of 4 quarters · filed 2013-03-18 | $141.64M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $15.00M 10-Q · filed 2012-08-07 | $27.00M derived: sum of 3 quarters · filed 2013-03-18 | $73.06M derived: sum of 4 quarters · filed 2013-03-18 | $136.89M 10-Q · filed 2011-08-09 | |
| 2011-03-31 | $8.00M 10-Q · filed 2012-05-10 | $20.00M derived: sum of 2 quarters · filed 2013-03-18 | $66.06M derived: sum of 3 quarters · filed 2013-03-18 | |||
| 2010-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $58.06M derived: sum of 2 quarters · filed 2013-03-18 | $78.17M 10-K · filed 2013-03-18 | |||
| 2010-09-30 | $46.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $66.17M 10-Q · filed 2011-11-08 | ||||
| 2010-06-30 | $20.12M 10-Q · filed 2011-08-09 | |||||
| 2009-12-31 | $11.04M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |